Calidi Biotherapeutics Financials - Benzinga

Calidi Biotherapeutics Inc

CLDIAMEX

Trade with Public

Trade with Public

$1.32

-0.065-4.69%

Last update: Sep 8, 10:38 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Stock Report

Calidi Biotherapeutics Financials

Calidi Biotherapeutics (CLDI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.

Benzinga Newsdesk

PRO
Calidi Biotherapeutics Q1 EPS $(0.43) Beats $(1.56) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(1.56) by 72.44 percent. This is a 80.09 percent increase over losses of $(2.16) per share

Benzinga Newsdesk

PRO
Calidi Biotherapeutics Q3 EPS $(2.21) Misses $(1.68) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.21) per share which missed the analyst consensus estimate of $(1.68) by 31.55 percent. This is a 71.67 percent increase over losses of $(7.80) per share

Benzinga Newsdesk

Nasdaq Down 1%; Lowe's Posts Upbeat Earnings

Avi Kapoor

Dow Surges 100 Points; Target Shares Fall After Q2 Results

Avi Kapoor

PRO
Calidi Biotherapeutics Q2 EPS $(1.99) Misses $(0.11) Estimate

Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.99) per share which missed the analyst consensus estimate of $(0.11) by 1709.09 percent. This is a 88.12 percent increase over losses of $(16.75) per

Benzinga Newsdesk